Inclusion Criteria:  Age of 18 to 65 years at the time of the screening visit (week -4) Willingness and availability to be followed for the planned duration of the study in one of the dedicated investigative centers Informed and signed consent Agree to be registered in the French Health Ministry computerised file (for France only) Being covered by the Health Insurance Willingness to understake HIV testing and receive HIV test results Willingness to discuss HIV infection risks, amenable to HIV risk reduction counseling, and committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit  Assessed by the clinic staff as being at "low risk" for HIV infection:  no history of injecting drug use in the previous ten years; no STI in the last six months, untreated or incompletely treated syphilis infection in the past; no high risk partner (e.g., injecting drug user, HIV positive partner) either currently or within the past six months; no unprotected anal intercourse in the last six months, outside a relationship with a regular partner known/presumed to be HIV negative; no unprotected vaginal intercourse in the last six months outside a relationship with a regular known/presumed HIV negative partner.  Participants who were born female: negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test performed on the day of initial IMP administration (week 0) and before randomisation  Reproductive status: if heterosexually active female, consistently using an effective method of contraception with partner for sexual activity that could lead to pregnancy from at least 21 days prior to enrolment through 4 months after the last administration. Effective contraception is defined as using any of the following methods:  Condoms (male or female) with or without a spermicide; Intrauterine device (IUD); Intrauterine hormone releasing system (IUS); Hormonal contraception (progesterone only); Successful vasectomy in the male partner (considered successful if a participant reports that a male partner has (i) documentation of azoospermia by microscopy, or (ii) a vasectomy more than 2 years ago with no resultant pregnancy despite unprotected sexual activity postvasectomy); Or not be of reproductive potential, such as having reached menopause (no menses for 1 year without an alternative medical cause) or having undergone hysterectomy, bilateral oophorectomy, or tubal ligation. Agree not to seek pregnancy including through alternative methods, such as artificial insemination or in vitro fertilization until 4 months after the last administration. Participants who were born male, if heterosexually active male, using an effective method of contraception with their partner from the first day of IMP administration until 4 months after the last administration. This also applies to sperm donation.  Normal biological values,  Hemoglobin ≥ 11.0 g/dL for participants who were born female, ≥ 13.0 g/dL for participants who were born male; White blood cell count = 3,300 to 12,000 cells/mm3; Total lymphocyte count ≥ 800 cells/mm3; Platelets = 125,000 to 550,000/mm3; Chemistry panel: ALT, AST, and alkaline phosphatase < 1.25 times the institutional upper limit of normal; creatinine <1.1x institutional upper limit of normal. Negative HIV-1 and -2 blood test; Negative Hepatitis B surface antigen (HBsAg); Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive.  Normal urine:  Negative urine glucose, and Negative or trace urine protein, and Negative or trace urine hemoglobin (if trace hemoglobin is present on dipstick, a microscopic urinalysis with red blood cells levels within institutional normal range).  Exclusion Criteria:  Person participing in another research involving the human person or participing in another research involving the human person with an exclusion period still in progress at screening (week -4) Intent to participate in another study of an investigational research agent during the planned duration of the study Participants who are not able to understand and to follow all required study procedures for the whole period of the study in the judgment of the investigator Under tutorship (only for France), guardianship, or deprived of liberty by a juridical or administrative decision Planned absence that could affect participation in the study (travel abroad, relocation, impending professional mutation...) Pregnant or breastfeeding  Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:  A process that would affect the immune response; A process that would require medication that affects the immune response; Any contraindication to repeated injections or blood draws; A condition that requires active medical intervention or monitoring to avert grave danger to the participant's health or well-being during the study period; A condition or process for which signs or symptoms could be confused with reactions to vaccine; Any condition specifically listed among the exclusion criteria below. Immunodeficiency  Asthma exclusion criteria:  Asthma other than mild, well-controlled asthma. (Symptoms of asthma severity as defined in the most recent National Asthma Education and Prevention Program (NAEPP) Expert Panel report).  Exclude a participant who:  Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or Uses moderate/high dose inhaled corticosteroids, or In the past year has either of the following: (i) Greater than 1 exacerbation of symptoms treated with oral/parenteral corticosteroids or (ii) Needed emergency care, urgent care, hospitalization, or intubation for asthma. Diabetes type 1 or type 2, including cases controlled with diet alone. (Not excluded: history of isolated gestational diabetes). Thyroidectomy, or thyroid disease requiring medication during the last 12 months  Hypertension:  If a person has been found to have elevated blood pressure or hypertension during screening or previously, exclude for blood pressure that is not well controlled. Well-controlled blood pressure is defined as consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be ≤ 150 mm Hg systolic and ≤ 100 mm Hg diastolic. For these participants, blood pressure must be ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic at enrolment; If a person has NOT been found to have elevated blood pressure or hypertension during screening or previously, exclude for systolic blood pressure ≥ 150 mm Hg at enrolment or diastolic blood pressure ≥ 100 mm Hg at enrolment. Contraindication to the IMPs including hypersensitivity BMI ≥ 40 kg/m2 ; ≤ 18 kg/m2 ; or BMI ≥ 35 kg/m2 with 2 or more of the following: age > 45, systolic blood pressure > 140 mm Hg, diastolic blood pressure > 90 mm Hg, current smoker, known hyperlipidemia Bleeding disorder diagnosed by a doctor (e.g., coagulation factor deficiency, coagulopathy, or platelet disorder requiring special precautions) Malignancy (Not excluded: participant who has had malignancy excised surgically and who, in the investigator's estimation, has a reasonable assurance of sustained cure, or who is unlikely to experience recurrence of malignancy during the period of the study) Asplenia: any condition resulting in the absence of a functional spleen Seizure disorder: History of seizure(s) within past three years. Also exclude if participant has used medications in order to prevent or treat seizure(s) at any time within the past 3 years. History of hereditary angioedema, acquired angioedema, or idiopathic angioedema. History of myocarditis, pericarditis, cardiomyopathy, congestive heart failure with permanent sequelae, clinically significant arrhythmia (including arrhythmia requiring medication, treatment, or clinical follow-up History of autoimmune disease Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence, assessment of safety or reactogenicity, or a participant's ability to give informed consent Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years. Serious adverse reactions to vaccines including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded: a participant who had a non-anaphylactic adverse reaction to pertussis vaccine as a child.) Investigational research agents received within 30 days before first IMP administration HIV vaccine(s) received in a prior HIV vaccine trial. For participants who have received control/placebo in an HIV vaccine trial, the investigator coordonnator will determine eligibility on a case-by-case basis. Non-HIV experimental vaccine(s) received within the last 5 years in a prior vaccine trial. Live attenuated vaccines (e.g., measles, mumps, and rubella [MMR]; varicella; yellow fever) received within 30 days before first IMP administration or scheduled within 28 days after one of the 3 injections according to the protocol Vaccines that are not live attenuated vaccines and were received within 21 days prior to first IMP administration (e.g., tetanus, pneumococcal, Hepatitis A or B) Blood products received within 120 days before first IMP administration Immunoglobulin received within 60 days before first IMP administration Current anti-tuberculosis (TB) prophylaxis or therapy Allergy treatment with antigen injections within 30 days before first IMP administration or that are scheduled within 14 days after first IMP administration Immunosuppressive medications received within last three months before first IMP administration. (Not excluded: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical corticosteroids for mild, uncomplicated dermatitis; or [4] a single course of oral/parenteral corticosteroids at doses < 2 mg/kg/day and length of therapy < 11 days with completion at least 30 days prior to enrolment)